165 results
6-K
EX-99.1
LEGN
Legend Biotech Corp
3 Jun 24
Current report (foreign)
4:05pm
” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating … , including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures
6-K
EX-99.1
LEGN
Legend Biotech Corp
23 May 24
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
5:00pm
, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include … protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political
6-K
EX-99.1
LEGN
Legend Biotech Corp
13 May 24
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
7:01am
regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act … in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed
6-K
LEGN
Legend Biotech Corp
13 May 24
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
7:01am
in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; the duration
6-K
EX-99.1
LEGN
Legend Biotech Corp
22 Apr 24
Current report (foreign)
1:06pm
regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act … in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed
6-K
11e tlf82wzz
16 Apr 24
Current report (foreign)
7:29am
6-K
EX-99.1
58aacqa qd4
8 Apr 24
Current report (foreign)
7:03am
F-3ASR
3piay
19 Mar 24
Automatic shelf registration (foreign)
7:57am
F-3ASR
EX-4.4
i3v9ew6r
19 Mar 24
Automatic shelf registration (foreign)
7:57am
6-K
EX-99.1
x0m z0yij6s
15 Mar 24
FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARITUDE-4 study
3:18pm
6-K
EX-99.1
f6g 0xraca
11 Mar 24
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
7:52am
6-K
EX-99.1
444u5n
23 Feb 24
Current report (foreign)
7:16am
6-K
o0bu8exuu1x
23 Jan 24
Legend Biotech Corporation 6-K
7:30am
6-K
EX-99.1
svhymvjib2wa rvfla2o
9 Jan 24
Legend Biotech Corporation 6-K
4:01pm
6-K
EX-99.1
3gjkot8 9cpq
11 Dec 23
Legend Biotech Corporation 6-K
7:32pm
6-K
lw7vq84x
20 Nov 23
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
6:02am
6-K
EX-99.1
580ti 7mejq47rytrhcw
20 Nov 23
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
6:02am